CN112805067B - Pad酶的吲哚及氮杂吲哚抑制剂 - Google Patents
Pad酶的吲哚及氮杂吲哚抑制剂Info
- Publication number
- CN112805067B CN112805067B CN201980064963.9A CN201980064963A CN112805067B CN 112805067 B CN112805067 B CN 112805067B CN 201980064963 A CN201980064963 A CN 201980064963A CN 112805067 B CN112805067 B CN 112805067B
- Authority
- CN
- China
- Prior art keywords
- methyl
- cyclopropylmethyl
- methoxy
- carbonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715850P | 2018-08-08 | 2018-08-08 | |
| US62/715,850 | 2018-08-08 | ||
| PCT/US2019/045466 WO2020033520A1 (en) | 2018-08-08 | 2019-08-07 | Indole and azaindole inhibitors of pad enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112805067A CN112805067A (zh) | 2021-05-14 |
| CN112805067B true CN112805067B (zh) | 2026-04-24 |
Family
ID=67766306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980064963.9A Active CN112805067B (zh) | 2018-08-08 | 2019-08-07 | Pad酶的吲哚及氮杂吲哚抑制剂 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11524959B1 (https=) |
| EP (1) | EP3833440A1 (https=) |
| JP (1) | JP7651451B2 (https=) |
| KR (1) | KR102885181B1 (https=) |
| CN (1) | CN112805067B (https=) |
| AR (1) | AR115920A1 (https=) |
| AU (1) | AU2019319835A1 (https=) |
| BR (1) | BR112021002091A2 (https=) |
| CA (1) | CA3108791A1 (https=) |
| CL (1) | CL2021000296A1 (https=) |
| CO (1) | CO2021001217A2 (https=) |
| EA (1) | EA202190462A1 (https=) |
| IL (1) | IL280650A (https=) |
| MX (1) | MX2021001565A (https=) |
| PE (1) | PE20211068A1 (https=) |
| SG (1) | SG11202101174RA (https=) |
| TW (1) | TW202019415A (https=) |
| WO (1) | WO2020033520A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| CN111943947B (zh) * | 2020-07-24 | 2021-04-30 | 重庆文理学院 | 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用 |
| AR123286A1 (es) | 2020-08-19 | 2022-11-16 | Bristol Myers Squibb Co | Compuestos de benzimidazol sustituidos útiles como inhibidores de tlr9 |
| AU2021328577A1 (en) | 2020-08-19 | 2023-03-23 | Bristol-Myers Squibb Company | 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2022140390A1 (en) * | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| CN117427074A (zh) * | 2023-11-13 | 2024-01-23 | 山东第一医科大学(山东省医学科学院) | 四氢喹啉醇作为铁死亡抑制剂在制备急性肾损伤药物中的应用 |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100594A1 (en) * | 2015-12-09 | 2017-06-15 | Padlock Therapeutics, Inc. | Bicyclic inhibitors of pad4 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101916443B1 (ko) | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
| KR20180005250A (ko) * | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| US10654814B2 (en) | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| CA3015482A1 (en) | 2016-02-23 | 2017-08-31 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| WO2018022897A1 (en) | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| US11026937B2 (en) | 2016-09-12 | 2021-06-08 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of PAD4 |
| JP7311228B2 (ja) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| MX2021001471A (es) | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| US20220348562A1 (en) | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
-
2019
- 2019-08-07 MX MX2021001565A patent/MX2021001565A/es unknown
- 2019-08-07 PE PE2021000171A patent/PE20211068A1/es unknown
- 2019-08-07 CN CN201980064963.9A patent/CN112805067B/zh active Active
- 2019-08-07 JP JP2021506683A patent/JP7651451B2/ja active Active
- 2019-08-07 WO PCT/US2019/045466 patent/WO2020033520A1/en not_active Ceased
- 2019-08-07 KR KR1020217006477A patent/KR102885181B1/ko active Active
- 2019-08-07 SG SG11202101174RA patent/SG11202101174RA/en unknown
- 2019-08-07 US US17/265,842 patent/US11524959B1/en active Active
- 2019-08-07 TW TW108128155A patent/TW202019415A/zh unknown
- 2019-08-07 CA CA3108791A patent/CA3108791A1/en active Pending
- 2019-08-07 EP EP19759141.5A patent/EP3833440A1/en active Pending
- 2019-08-07 BR BR112021002091-8A patent/BR112021002091A2/pt not_active Application Discontinuation
- 2019-08-07 AR ARP190102237A patent/AR115920A1/es not_active Application Discontinuation
- 2019-08-07 AU AU2019319835A patent/AU2019319835A1/en not_active Abandoned
- 2019-08-07 EA EA202190462A patent/EA202190462A1/ru unknown
-
2021
- 2021-02-03 CO CONC2021/0001217A patent/CO2021001217A2/es unknown
- 2021-02-03 CL CL2021000296A patent/CL2021000296A1/es unknown
- 2021-02-04 IL IL280650A patent/IL280650A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100594A1 (en) * | 2015-12-09 | 2017-06-15 | Padlock Therapeutics, Inc. | Bicyclic inhibitors of pad4 |
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021001217A2 (es) | 2021-02-26 |
| JP2021534108A (ja) | 2021-12-09 |
| KR20210042934A (ko) | 2021-04-20 |
| CA3108791A1 (en) | 2020-02-13 |
| AR115920A1 (es) | 2021-03-10 |
| EP3833440A1 (en) | 2021-06-16 |
| AU2019319835A1 (en) | 2021-03-25 |
| SG11202101174RA (en) | 2021-03-30 |
| IL280650A (en) | 2021-03-25 |
| WO2020033520A1 (en) | 2020-02-13 |
| CN112805067A (zh) | 2021-05-14 |
| BR112021002091A2 (pt) | 2021-05-04 |
| JP7651451B2 (ja) | 2025-03-26 |
| US11524959B1 (en) | 2022-12-13 |
| EA202190462A1 (ru) | 2021-06-03 |
| MX2021001565A (es) | 2021-04-19 |
| PE20211068A1 (es) | 2021-06-09 |
| CL2021000296A1 (es) | 2021-06-25 |
| KR102885181B1 (ko) | 2025-11-11 |
| TW202019415A (zh) | 2020-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112805067B (zh) | Pad酶的吲哚及氮杂吲哚抑制剂 | |
| CN112566916B (zh) | 作为pad4抑制剂的经取代的噻吩并吡咯 | |
| JP7434281B2 (ja) | Ｐａｄ酵素のベンズイミダゾール阻害剤 | |
| JP7711073B2 (ja) | 免疫抑制剤として有用な大環状ｐａｄ４阻害剤 | |
| JP7483678B2 (ja) | Ｐａｄ４阻害剤としての置換ベンズイミダゾール | |
| EP4531843A1 (en) | Heterocyclic pad4 inhibitors | |
| WO2026075941A1 (en) | Pyridazinone derivatives as pad4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |